Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

A Phase 1/2 Study of Selinexor in Combination with Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Sponsor:Karyopharm Inc.
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAT0359
U.S. Government ID:NCT04421378
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of this research study is to see if the combination of medications approved for the treatment of glioblastoma, together with the study drug, selinexor (also known as XPOVIO), has any effects on your cancer. Selinexor works by trapping tumor suppressor proteins within the cell nucleus. This is expected to cause the cancer cells to die or stop growing. Selinexor is approved by the U.S. Food and Drug Administration (FDA) for the use in certain patients with multiple myeloma but has not yet been approved by the FDA for the treatment of your type of cancer.

Do You Qualify?
Are you 18 years of age or older?YesNo
Do you have a confirmed diagnosis of glioblastoma?YesNo
Are you willing to provide tumor tissue and blood samples for future genetic testing?YesNo
Submit
Cancel
Investigator
Andrew Lassman, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162